The cost effectiveness of B-Type natriuretic peptide measurement in the primary care setting-a UK perspective.
Collinson
Paul O
PO
Department of Chemical Pathology, St. George's Hospital, London, England. paul.collinson@stgeorges.nhs.uk
D000465:Algorithms; D015415:Biomarkers / Q000097:blood; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D004417:Dyspnea / Q000175:diagnosis; D006333:Heart Failure / Q000175:diagnosis* / Q000503:physiopathology; D006801:Humans; D008403:Mass Screening / Q000191:economics* / Q000379:methods; D017059:Models, Econometric; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011320:Primary Health Care / Q000191:economics* / Q000379:methods; D011379:Prognosis; D006113:United Kingdom
D015415:Biomarkers; D020097:Natriuretic Peptide, Brain